The study aimed to improve the treatment of impetigo
with naturally
occurring quercetin and its copper–quercetin (Cu–Q)
complex by preparing sustained-release (SR) nanoparticles of polycaprolactone
(PCL). The solvent evaporation method was used for the copper–quercetin
(Cu–Q) complex formation, and their PCL nanoparticles (PCL-NPs,
Q-PCL-NPs, and Cu-Q-PCL-NPs) were prepared by the high-pressure homogenization
method. Synthesis of nanoparticles was confirmed by their physicochemical
and antibacterial properties of quercetin against Gram-positive as
well as Gram-negative bacteria. The percentage loading efficiency
of quercetin and release in 100 mM of phosphate buffer pH 7.4 and
5.5 at 37 °C was found to be more than 90% after 24 h with the
zero-order release pattern. Minimum inhibitory concentration of nanoparticles
was found to increase threefold in the case of Cu-Q-PCL-NPs may be
due to the synergistic antibacterial behavior. Scanning electron microscopy
showed spherical nanoparticles, and surface roughness was confirmed
by atomic force microscopy analysis. Fortunately, no sign of irritation
on rat skin even at 3%, was seen. In vitro antioxidant assay by 2,2-diphenyl-1-picrylhydrazyl
reduction was found to be ≤80 ± 0.02% which confirmed
their scavenging activity. Interestingly, for the ex vivo study, the
tape-stripping model was applied against Staphylococcus
aureus containing rats and showed the formation of
the epidermal layer within 4–5 days. Confirmation of antibacterial
activity of pure quercetin, from Cu–Q complex, and their SR
release from Q-PCL-NPs and Cu-Q-PCL-NPs was considered an effective
tool for the treatment of skin diseases and can be used as an alternative
of already resistant ciprofloxacin in impetigo.